Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
PALO ALTO, Calif. & NEW YORK--( BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
“The positive top-line Phase 2a data for EVO301 marks an important milestone for Evommune and further validates IL-18 inhibition as a compelling approach for patients living with AD. We look forward to advancing the program forward and exploring an optimal dosing regimen for this potentially front-line biologic for AD,” said Luis Peña, President and Chief Executive Officer at Evommune. “We’ve nearly completed patient enrollment in the EVO756 Phase 2b trial in CSU, and plan to share top-line data in the second quarter. Additionally, the EVO756 Phase 2b trial in AD remains on track to report data in the second half of the year. MRGPRX2 antagonism is unique in its potential to modulate both mast cells and sensory neurons and we are eager to show the potential of MRGPRX2 inhibition in patients suffering from these debilitating diseases."
Mr. Peña continued, “We recently strengthened our cash position with a $125 million private placement, which increases our ability to move EVO301 into deeper development and to expand our development programs as we look to make a major impact in the treatment of chronic inflammatory diseases. We continue to execute across our pipeline, underscoring our focus on delivering new medicines to patients, and I am very proud of the work being done by the entire Evommune team.”
Business Highlights, Recent Developments and Upcoming Milestones
EVO756 – Oral MRGPRX2 Antagonist Program:
First-in-class, potent and highly selective oral small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor predominantly found on mast cells and peripheral sensory neurons.
EVO301 – Injectable IL-18 Binding Protein Fusion Protein:
Long-acting fusion protein consisting of an IL-18 binding protein and an anti-serum albumin Fab-associated domain with potential for more effective distribution to inflamed tissues than traditional monoclonal antibodies.
Recent Corporate Highlights
Upcoming Events
Fourth Quarter and Full Year 2025 Financial Results
About Evommune, Inc.
Evommune, Inc., is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company’s mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation. For more information, please visit www.evommune.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are “forward-looking statements.” These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the potential therapeutic benefit of EVO756 and EVO301, the design, objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of the Company’s product candidates, including the ongoing Phase 2 clinical trials for EVO756 and EVO301; anticipated cash runway through 2028; and continued advancement of the Company’s portfolio. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company’s limited operating history and historical losses; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; the impacts of macroeconomic conditions, including heightened inflation and uncertain credit and financial markets, on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company’s ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the Company’s ability to obtain, maintain and protect its intellectual property; and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading “Risk Factors” in the Company’s Quarterly Report on Form 10-Q, filed with the SEC on December 11, 2025, and in other filings that the Company makes and will make with the SEC in the future. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Evommune, Inc.
Unaudited Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
(unaudited)
Three Months Ended
Year Ended
December 31,
December 31,
2025
2024
2025
2024
Revenues:
License revenue
$
—
$
—
$
13,000
$
7,000
Operating expenses:
Research and development
20,403
17,831
74,042
64,244
General and administrative
9,313
3,623
20,029
12,769
Total operating expenses
29,716
21,454
94,071
77,013
Loss from operations
(29,716
)
(21,454
)
(81,071
)
(70,013
)
Total other income, net
1,443
728
12,201
3,205
Net loss
(28,273
)
(20,726
)
(68,870
)
(66,808
)
Net loss attributable to common stockholders
(28,273
)
(20,726
)
(68,870
)
(66,808
)
Basic and diluted net loss per share of common stock
$
(1.43
)
$
(13.58
)
$
(11.22
)
$
(44.29
)
Weighted average basic and diluted shares of common stock outstanding
19,775,940
1,525,928
6,136,636
1,508,284
Evommune, Inc.
Unaudited Condensed Consolidated Balance Sheets
(in thousands)
December 31,
December 31,
2025
2024
Cash, cash equivalents and short-term investments
$
149,200
$
72,040
Other current assets
4,278
1,948
Other non-current assets
71,468
2,067
Total assets
$
224,946
$
76,055
Current liabilities
$
17,909
$
27,981
Other non-current liabilities
1,471
535
Total liabilities
19,380
28,516
Convertible preferred stock
—
191,776
Total stockholders’ equity (deficit)
205,566
(144,237
)
Total liabilities, convertible preferred stock, and stockholders’ equity (deficit)
$
224,946
$
76,055